Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05081167 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess the Efficacy and Safety of REL-1017 as Monotherapy for Major Depressive Disorder (MDD)
A Phase 3 study of Major Depressive Disorder, sponsored by Relmada Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 232
- Enrollment target
- 10
- Study locations
NCT05081167 is a Phase 3 study of Major Depressive Disorder that has completed, run by Relmada Therapeutics. The registered enrollment target is 232 participants, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (38% lower). The trial reports 10 study locations across 4 states.
The verdict
NCT05081167, a Phase 3 study of Major Depressive Disorder, has completed, sponsored by Relmada Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 232 participants
- Enrollment target
- 10
- Study locations
Study Summary
This is an outpatient, 2-arm, Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of REL-1017 once daily (QD) as a monotherapy for Major Depressive Disorder.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG REL-1017
Study Locations (10)
Florida
- Relmada Site - Maitland
- Relmada Site - Miami
- Relmada Site - Miami
- Relmada Site - Miami Springs
- Relmada Site - Orlando
- Relmada Site - Palm Bay
Massachusetts
- Relmada Site - Boston
- Relmada Site - Watertown
Illinois
- Relmada Site - Chicago
Texas
- Relmada Site - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 232 participants |
| Start Date | 2021-06-02 |
| Est. Completion | 2022-09-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05081167
The ClinicalTrials.gov registry entry for NCT05081167 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 232 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (38% lower). The listed sponsor is Relmada Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05081167 reports 10 study locations spanning 4 distinct geographic areas - top geographies include Florida, Massachusetts, Illinois.
Frequently Asked Questions
What is clinical trial NCT05081167 about?
NCT05081167 is a clinical study titled "A Study to Assess the Efficacy and Safety of REL-1017 as Monotherapy for Major Depressive Disorder (MDD)". This is an outpatient, 2-arm, Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of REL-1017 once daily (QD) as a monotherapy for Major Depressive Disorder.
What is the current status of trial NCT05081167?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 232 participants. The study started on 2021-06-02. Estimated completion is 2022-09-14.
What conditions does trial NCT05081167 study?
This clinical trial studies the following conditions: Major Depressive Disorder.
What interventions are being tested in trial NCT05081167?
The interventions under investigation include: Placebo (DRUG), REL-1017 (DRUG).
Who is sponsoring clinical trial NCT05081167?
This trial is sponsored by Relmada Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05081167 being conducted?
This trial has 10 study locations across Florida, Illinois, Massachusetts, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 3
-
Study to Assess the Safety and Effectiveness of NMRA-335140-501
RECRUITING · Phase 3
-
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 3
-
The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder
RECRUITING · Phase 3
-
"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"
RECRUITING · Phase 3
-
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.